01—Abstract
Summary
Summary of the 10-K filed February 11, 2026. Cited figures are marked; the original filing is the authoritative source.
Royalty Pharma plc (RPRX) reported 2025 Portfolio Receipts of $3.3 billiona ($3,254,361 thousand), up from $2.80 billion in 2024, with Royalty Receipts of $3.13 billion.
Total income and other revenues rose 5.1% to $2.38 billionb, but consolidated net income was roughly flat at $1.32 billion and net income attributable to Royalty Pharma plc fell 10.2% to $770.9 million. The decline was driven by a $1.03 billion swing in the provision for changes in expected cash flows (a $295.8 million provision income in 2025 versus $732.5 million expense in 2024), a $336.8 million increase in G&A expenses (largely share-based compensation following the May 2025 Internalization), and $450.0 million of R&D funding expense, partly offset by a $267.1 million increase in operating income. The company deployed $2.6 billion of cash on royalties, milestones and other contractual receipts in 2025, returned $511.9 million through dividends and distributions and repurchased $1.2 billion of Class A shares, and ended the year with $9.2 billion of principal borrowings against $618.7 million of cash.
Net cash from operating activities was $2.49 billionc, down from $2.77 billion. The filing notes ongoing dispute resolution with Vertex over Alyftrek royalty receipts, and states that Vertex accounted for 35% of 2025 total income and other revenues. For investors, the key items are the strong growth in cash receipts and the large non-cash swings in GAAP income from the effective interest accounting model, alongside higher leverage, higher interest expense ($307.7 million, up 36.4%) and the increased compensation cost of the Internalization.
02—Key points
Key Highlights
- Portfolio Receipts rose 16.2% to $3.25 billion in 2025 from $2.80 billion, excluding the $511 million MorphoSys Development Funding Bonds sale.
- Income from financial royalty assets increased 5.2% to $2.26 billion; Voranigo contributed $154.4 million versus $46.2 million in 2024.
- Net income attributable to Royalty Pharma plc declined 10.2% to $770.9 million, with diluted EPS of $1.78 versus $1.91 in 2024.
- Provision for changes in expected cash flows swung to $295.8 million of income in 2025 from $732.5 million of expense in 2024.
- G&A expenses rose 142.3% to $573.5 million, including $290.9 million of share-based compensation following the May 16, 2025 Internalization.
- Capital deployment of $2.6 billion in 2025 against $4.7 billion of announced transactions; $1.2 billion of Class A shares repurchased.
- Senior unsecured debt principal reached $9.2 billion at year end, with interest expense up 36.4% to $307.7 million and $1.8 billion of revolving capacity available.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2025filed February 11, 2026Financial Statements
FY2025 against FY2024
| Line item | FY2025FY2024 | Change |
|---|---|---|
| Revenue | $2.38B$2.26B | +5.1% |
| R&D Expenses | $452.00M$2.00M | +22500.0% |
| Operating Expenses | $818.67M$971.13M | −15.7% |
| Operating Income | $1.56B$1.29B | +20.7% |
| Net Income | $770.95M$858.98M | −10.2% |
| EPS (Basic) | $1.79$1.92 | −6.8% |
| EPS (Diluted) | $1.78$1.91 | −6.8% |
| Shares Outstanding (Basic) | 429.80M448.19M | −4.1% |
| Shares Outstanding (Diluted) | 564.46M594.11M | −5.0% |
05—Questions
Frequently Asked Questions
How did Royalty Pharma's cash generation perform in 2025?
Portfolio Receipts were $3.25 billion in 2025, up 16.2% from $2.80 billion in 2024. Royalty Receipts were $3.13 billion, and the cystic fibrosis franchise was the largest contributor at $916.9 million.
Why did net income attributable to Royalty Pharma plc decline in 2025?
Net income attributable to Royalty Pharma plc fell 10.2% to $770.9 million. The filing attributes this mainly to higher G&A expenses from share-based compensation after the Internalization, $450.0 million of R&D funding expense, and the change in provision income versus the prior-year provision expense, partly offset by higher income from financial royalty assets.
What is the Internalization and how does it affect future costs?
On May 16, 2025, Royalty Pharma acquired its former external manager, RP Manager, and became internally managed. It no longer pays Management Fees, but it now bears employee compensation and other overhead directly, and the filing notes approximately 22.8 million RP Holdings Class E Interests with $646.5 million of unrecognized compensation expense still to be recognized.
How concentrated is the portfolio and what is the Vertex dispute?
The top five product franchises accounted for 61% of 2025 Royalty Receipts, and Vertex accounted for 35% of total income and other revenues. Beginning in the second quarter of 2025, the company did not receive the full Alyftrek royalty receipts it believes it is entitled to and has started dispute resolution procedures; any recovery will be recognized only upon resolution in its favor.
How did the company return capital to shareholders and manage its debt in 2025?
Shareholders received four quarterly dividends of $0.22 per Class A share totaling $378.3 million. The company repurchased $1.2 billion of Class A shares and had about $1.8 billion remaining under its $3.0 billion program. It issued $2.0 billion of senior unsecured notes in September 2025 and repaid $1.0 billion of debt; the weighted average coupon on its notes was 3.75%.
06—Continue